Payment overview · 2025
General Payments
$129.77
8 reported records · 5 companies
Healthcare provider profile · identity verified
Sanjay Vyas, DO
Allopathic & Osteopathic Physicians|Family Medicine · GREENWOOD, IN · NPI 1295708766
Verified facts
What the public records show
CMS Open Payments records show Sanjay Vyas, DO received $129.77 in general payments during 2025 across 8 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.37 | 27.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.03 | 26.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.57 | 25.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.15 | 10.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.65 | 10.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $129.77 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.37 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.03 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.57 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
91 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1101 | 310 |
| Levothyroxine Sodium | Levothyroxine Sodium | 570 | 149 |
| Omeprazole | Omeprazole | 452 | 132 |
| Alprazolam | Alprazolam | 433 | 75 |
| Simvastatin | Simvastatin | 423 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 393 | 119 |
| Lisinopril | Lisinopril | 393 | 118 |
| Metformin Hcl | Metformin Hcl | 378 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 361 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 336 | 104 |
| Gabapentin | Gabapentin | 333 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 285 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 251 | 85 |
| Losartan Potassium | Losartan Potassium | 221 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 72 |
| Glipizide | Glipizide | 212 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 196 | 63 |
| Fenofibrate | Fenofibrate | 195 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 186 | 59 |
| Diclofenac Sodium | Diclofenac Sodium | 171 | 74 |
| Sertraline Hcl | Sertraline Hcl | 166 | 43 |
| Atenolol | Atenolol | 160 | 43 |
| Meloxicam | Meloxicam | 152 | 52 |
| Cephalexin | Cephalexin | 151 | 114 |
| Furosemide | Furosemide | 151 | 52 |
| Trazodone Hcl | Trazodone Hcl | 150 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 146 | 42 |
| Tramadol Hcl | Tramadol Hcl | 146 | 37 |
| Gemfibrozil | Gemfibrozil | 145 | 44 |
| Fluoxetine Hcl | Fluoxetine Hcl | 136 | 40 |
| Potassium Chloride | Potassium Chloride | 135 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 45 |
| Ezetimibe | Ezetimibe | 123 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 28 |
| Allopurinol | Allopurinol | 116 | 28 |
| Carvedilol | Carvedilol | 116 | 33 |
| Spironolactone | Spironolactone | 111 | 33 |
| Prednisone | Prednisone | 108 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 34 |
| Clonazepam | Clonazepam | 103 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 31 |
| Eliquis | Apixaban | 101 | 21 |
| Montelukast Sodium | Montelukast Sodium | 99 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 26 |
| Lorazepam | Lorazepam | 94 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 27 |
| Synthroid | Levothyroxine Sodium | 91 | 24 |
| Warfarin Sodium | Warfarin Sodium | 90 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 29 |
| Celecoxib | Celecoxib | 82 | 26 |
| Alendronate Sodium | Alendronate Sodium | 81 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 75 | 23 |
| Buspirone Hcl | Buspirone Hcl | 70 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 15 |
| Baclofen | Baclofen | 66 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 16 |
| Acyclovir | Acyclovir | 65 | 27 |
| Januvia | Sitagliptin Phosphate | 62 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 17 |
| Amoxicillin | Amoxicillin | 58 | 39 |
| Finasteride | Finasteride | 57 | 16 |
| Topiramate | Topiramate | 56 | suppressed |
| Glimepiride | Glimepiride | 52 | 20 |
| Valsartan | Valsartan | 52 | 17 |
| Lovastatin | Lovastatin | 50 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 18 |
| Ibandronate Sodium | Ibandronate Sodium | 48 | 17 |
| Famotidine | Famotidine | 47 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 14 |
| Metformin Hcl Er | Metformin Hcl | 44 | 13 |
| Torsemide | Torsemide | 44 | 12 |
| Levofloxacin | Levofloxacin | 43 | 33 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | 12 |
| Fluconazole | Fluconazole | 33 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Glipizide Er | Glipizide | 32 | 12 |
| Naproxen | Naproxen | 32 | 14 |
| Promethazine Hcl | Promethazine Hcl | 32 | 19 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | 13 |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 13 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | 12 |
| Linzess | Linaclotide | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Ramipril | Ramipril | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 22 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129.77 · 8 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, CAPLYTA, EVENITY, PENBRAYA, PREVNAR 20, TRELEGY ELLIPTA, TRUMENBA, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error